SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-299375
Filing Date
2022-12-06
Accepted
2022-12-06 16:06:08
Documents
13
Period of Report
2022-12-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d356648d8k.htm   iXBRL 8-K 25240
2 EX-10.1 d356648dex101.htm EX-10.1 9999
  Complete submission text file 0001193125-22-299375.txt   163636

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA amlx-20221201.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE amlx-20221201_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amlx-20221201_pre.xml EX-101.PRE 11706
7 EXTRACTED XBRL INSTANCE DOCUMENT d356648d8k_htm.xml XML 3463
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

IRS No.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 221447692
SIC: 2834 Pharmaceutical Preparations